NEW YORK, March 7 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc.
(GBI) - (OTCBB:GBIW) and its business advisor, Experigen Management Company
(Experigen) announced today that Lou Lome has joined GBI as a Scientific
Mr. Lome is noted for his scientific contributions spanning three decades
of service to the United States government at the highest levels of science at
the Office of Research and Development at the Central Intelligence Agency, the
Innovative Science & Technology Office of the Strategic Defense Initiative
Organization, the Department of Defense Science and Technology Program in
Electronic Warfare, and most recently as a research scientist for the
Institute for Defense Analysis (IDA). Mr. Lome's experience includes
technology innovation in communications and information technology, VLSI,
image and signal processing programs, advanced information surveillance,
quantum computing, and nanotechnology.
"We are very pleased Mr. Lome has joined GBI's advisory team," said Greg
McCartney, President of GBI. "His outstanding science background, his
extensive network of world leading scientists and his in-depth experience in
large scale project management becomes very important to our success as we
continue to build GBI and manage our current investment companies to
"We are very serious about increasing GBI's commercial and scientific
focus," said Douglas C. Lane of Experigen. "Mr. Lome's experience in advanced
satellite surveillance systems and RFID devices will help us exploit a new and
potentially exciting channel to our Prion Developmental Laboratory company's
opportunities: animal tracking and record maintenance systems that are
becoming an increasing mandate of the beef import and export industry by
foreign and domestic governments. And, with Mr. Lome's participation, we now
stand to benefit from synergies in oncology and nanotechnology that are being
developed globally which complement and may increase our Biomedical
Diagnostic, Inc. company's MSA breast cancer diagnostic technology, and
possible therapeutic opportunities that may develop as a result."
Mr. Lome is also an advisor to the International Technology Roadmap for
Semiconductors (ITRS), Emerging Research Devices (ERD), NASA Jet Propulsion
Laboratory, Oak Ridge National Laboratory, and the Nanotechnology Science &
Technology Institute. He is a member of over twenty exclusive science
professional societies, including senior member of the Institute for
Electrical and Electronic Engineers (IEEE), life member of the American
Physical Society (APS), fellow of the Optical Society of America (OSA),
Society for Photo-optical Interpretation Engineers (SPIE), Society for
Mathematical Biology (SMB), among others, and he is Chair of numerous
conferences within IEEE and SPIE, and the Nanotech 2005 Government Forum.
Experigen is a management company retained by Genesis Bioventures, Inc.
to develop and advance GBI's investment portfolio, financing and operations.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation
focusing on the development and marketing of novel diagnostics and
therapeutics in oncology and neurodegenerative diseases.
Statements in this press release that are not strictly historical facts
are "forward looking" statements (identified by the words "believe",
"estimate", "project", "expect" or similar expressions) within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements
inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not limited to,
continued acceptance of the Company's products and services in the
marketplace, competitive factors, changes in the regulatory environment, and
other risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. The statements in this press release are
made as of today, based upon information currently known to management, and
the Company does not undertake any obligation to publicly update or revise any
GBI Investor Relations: (604) 542-0820, email@example.com,
Experigen: (310) 443-4100, firstname.lastname@example.org, www.experigen.com
SOURCE Genesis Bioventures, Inc.